(Q34149569)

31 July 2017

title

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy (English)

1 reference

31 July 2017

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy (English)

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

25 August 2024

0 references

1 reference

Axel Hoos

1

1 reference

31 July 2017

Ramy Ibrahim

2

1 reference

31 July 2017

Alan Korman

3

1 reference

31 July 2017

Kald Abdallah

4

1 reference

31 July 2017

David Berman

5

1 reference

31 July 2017

Vafa Shahabi

6

1 reference

31 July 2017

Kevin Chin

7

1 reference

31 July 2017

Renzo Canetta

8

1 reference

31 July 2017

Rachel Humphrey

9

1 reference

31 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21074069

25 August 2024

publication date

1 October 2010

1 reference

full work available at URL

31 July 2017

https://doi.org/10.1053/j.seminoncol.2010.09.015

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21074069

https://api.elsevier.com/content/article/PII:S0093775410001697?httpAccept=text/xml

25 August 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

https://api.elsevier.com/content/article/PII:S0093775410001697?httpAccept=text/plain

25 August 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

25 August 2024

1 reference

31 July 2017

volume

37

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

533-546

1 reference

CTLA-4 can function as a negative regulator of T cell activation

31 July 2017

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1016/1074-7613(94)90071-X

Immunotherapy: past, present and future

1

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications.

25 August 2024

2

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

The Concept of Immunological Surveillance

25 August 2024

4

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

The three Es of cancer immunoediting

25 August 2024

5

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Principles of cancer therapy: oncogene and non-oncogene addiction

25 August 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Next generation of immunotherapy for melanoma

25 August 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Immunotherapy for advanced melanoma.

25 August 2024

8

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Immune therapy for cancer

25 August 2024

9

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Betting on immunotherapy for melanoma

25 August 2024

10

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

A clinical development paradigm for cancer vaccines and related biologics

25 August 2024

11

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

25 August 2024

12

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Improved Endpoints for Cancer Immunotherapy Trials

25 August 2024

13

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Immunostimulatory monoclonal antibodies for cancer therapy

25 August 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

25 August 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

25 August 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Cancer and immune response: old and new evidence for future challenges.

25 August 2024

18

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

25 August 2024

19

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule

25 August 2024

20

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1

25 August 2024

21

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Costimulation blockade with belatacept in renal transplantation

25 August 2024

22

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

25 August 2024

23

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo

25 August 2024

24

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

25 August 2024

25

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

25 August 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Enhancement of antitumor immunity by CTLA-4 blockade

25 August 2024

27

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages

25 August 2024

28

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

25 August 2024

29

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism

25 August 2024

30

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

25 August 2024

31

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

25 August 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

25 August 2024

34

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice

25 August 2024

35

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques

25 August 2024

36

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb

25 August 2024

37

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Phase I/II study of ipilimumab for patients with metastatic melanoma

25 August 2024

38

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

25 August 2024

39

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

25 August 2024

40

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

25 August 2024

41

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

25 August 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Ipilimumab: controversies in its development, utility and autoimmune adverse events

25 August 2024

43

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma

25 August 2024

44

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

25 August 2024

45

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

25 August 2024

46

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

25 August 2024

49

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

25 August 2024

50

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

25 August 2024

51

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

25 August 2024

53

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

25 August 2024

54

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Complete regression of a previously untreated melanoma brain metastasis with ipilimumab

25 August 2024

55

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy

25 August 2024

59

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

25 August 2024

60

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

25 August 2024

64

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation

25 August 2024

66

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

25 August 2024

67

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma

25 August 2024

68

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

25 August 2024

69

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Regulatory T cells: overcoming suppression of T-cell immunity

25 August 2024

70

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

25 August 2024

71

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

25 August 2024

72

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

25 August 2024

73

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

25 August 2024

74

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

25 August 2024

76

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

25 August 2024

78

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma

25 August 2024

79

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.09.015

25 August 2024

Identifiers

1 reference

31 July 2017

1 reference